MarketWatch
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
View original source — MarketWatch ↗
Related stories
Bloomberg
HealthJun 9, 2026 · 1 min
GSK Agrees to Buy Nuvalent for $10.6 Billion
Bloomberg
Financial Times
HealthJun 9, 2026 · 1 min
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Financial Times
CNBC
HealthJun 9, 2026 · 1 min
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
CNBC
Financial Times
HealthJun 19, 2026 · 1 min
AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics
Financial Times